Skip to main content

Heft Nr. 1/2025

Heft Nr. 1/2025

Anzeigenschluss: 05.02.2025
Erscheinungstermin: 28.02.2025

Download als PDF

Fortbildung

  • CME: Tabakentwöhnung – so schaffen es Ihre Patienten
  • Fortbildung: Gesundheitliche Risiken durch Cannabiskonsum: Kiffen, Vapen, Dabben – die Lunge leidet immer 
  • Fortbildung: COPD und Sport

Journal Club

  • YouTube-videos for patient education in lymphangioleiomyomatosis? 
  • Coaching doctors to improve ethical decision-making in adult hospitalized patients potentially receiving excessive treatment. The CODE stepped-wedge cluster randomized controlled trial 
  • Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial 
  • Sorin et al (2024) Neoadjuvant chemoimmunotherapy for NSCLC (Non Small Cell Lung Cancer). A systematic review and meta-analysis 
  • Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
  • Progressive Early Interstitial Lung Abnormalities in Persons at Risk for Familial Pulmonary Fibrosis: A Prospective Cohort Study 
  • Prevalence and Clinical Correlates of Radiologically Detected Coronary Artery Disease in COPD: A Cross-Sectional Observational Study 
  • Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype 
  • Rapid multiplex PCR panel for pneumonia in hospitalised patients with suspected pneumonia in the USA: a single-centre, open-label, pragmatic, randomised controlled trial
  • Prognostic impact of targetable driver alterations in resected early-stage lung cancer


*Die Redaktion behält sich aktuelle Änderungen vor.